arrow
T

Thomas Pabst

University of Bern
H指数:46
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022

2016年至2022年间EBMT中心中,17p缺失的骨髓瘤患者在接受AHSCT时,细胞遗传学异常的累积效应对其预后的影响

2026-09-050
OAAI
Feasibility and safety of rapid glofitamab ramp-up

快速提升glofitamab的可行性与安全性

Leukemia
IF13.4
2026-07-010
OAAI
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)

IPI风险因素对复发或难治性大B细胞淋巴瘤(LBCL)治疗中CAR T细胞疗法或同种异体干细胞移植的影响

2026-06-190
PRE
Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study

异基因造血细胞移植治疗T细胞/组织细胞富集型大B细胞淋巴瘤:一项EBMT淋巴瘤工作组研究

Leukemia
IF13.4
2026-06-150
OAAI
CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target

CD70/CD27信号通路促进多发性骨髓瘤的发病机制,并代表一个有前景的 therapeutic target。

Leukemia
IF13.4
2026-03-230
OAAI
Can hyperleukocytosis be caused by a non-hematologic condition? A 10-year retrospective tertiary-care center cohort study

高白细胞血症可由非血液系统疾病引起吗?一项为期10年的回顾性三级医疗机构队列研究

2026-02-280
OA
MDS/AML AND AML WITH MYELODYSPLASIA-RELATED GENE MUTATIONS: CLINICAL AND MOLECULAR SIMILARITIES

MDS/AML和AML伴骨髓增生异常相关基因突变: 临床和分子相似性

2026-01-160
OAAI
Hemophagocytic Syndromes in Adults: Real-World Data on Mortality from a Tertiary Reference Center

成人噬血细胞综合征:来自三级参考中心的真实世界死亡率数据

2025-12-010
OA
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers

炎症为基础评分在复发/难治性LBCL患者接受CD3xCD20双特异性T细胞接合物治疗中的预后价值

2025-10-240
OAAI